ProShares Trust - ProShares Ultra Ether ETF
ETHT
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.66B
Close$
$0.06
99.4% downside
Current Fair Value
99.4% downsideOvervalued by 99.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $31.66 Billion |
|---|---|
| Enterprise Value | $31.48 Billion |
| Dividend Yield | $1.77 (13.53%) |
| Earnings per Share | $-0.04 |
| Beta | 5.65 |
| Outstanding Shares | 87,237,000 |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | -339.28 |
|---|---|
| PEG | -59.45 |
| Price to Sales | - |
| Price to Book Ratio | 3.35 |
| Enterprise Value to Revenue | 2410.83 |
| Enterprise Value to EBIT | -418.83 |
| Enterprise Value to Net Income | -447 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2150▼ 38.65% |
|---|---|
| Total Calls | 144,200▼ 17.08% |
| Total Puts | 31,000▼ 70.36% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.34%▼ 0.03% |
|---|---|
| Total Invested | $4.39M▼ 63.44% |
| Investors Holding | 24▲ 5.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...